
Residents concerned about Goodyear plant urged to get active
Jan. 30—Niagara Falls residents with concerns about the release of a known chemical carcinogen from the Goodyear Rubber & Tire Co. plant off 56th Street were urged Thursday to get organized, get active and get vocal.
Representatives from six environmental and community advocacy groups held an informational meeting at New Hope Baptist Church where they encouraged about 50 attendees to contact their elected officials to tell them to take action to protect public health in the neighborhood where Goodyear operates.
"It is time for us to set up a coalition and that coalition is each and every one of you that are here," said Renae Kimble, president of the Niagara Falls Chapter of the NAACP.
The primary concern remains the plant's emission of Ortho-Toluidine, a chemical used in the production of tires that has been linked to incidences of bladder cancer among workers in the past.
While the state changed its guidelines to reduce the allowable output of the chemical in 2021, the facility has for years operated under earlier, less stringent standards.
DEC officials contend, based on existing data, that the situation does not pose an "imminent" health risk to neighboring home and business owners.
Advocates for changes inside the plant aren't buying it.
"We call on our government agencies and officials to protect our community now before it is too late," Kimble said. "It should not be about dollars and cents. Our health is paramount, more than anything else."
The World Health Organization classified O-T as a known human carcinogen in 2008. The state's 2021 release requirements for the chemical classified it as a "high toxicity contaminant." According to the federal Center for Disease Control, O-T exposure can cause bladder cancer, anemia, dizziness, headaches, confusion, eye, skin and breathing irritation as well as skin lesions.
Under previous O-T limits, Goodyear was allowed to emit up to 5,000 pounds of the material into the air per year. Under the 2021 limits, the company's output should have been reduced to no more than 100 pounds per year.
In 2022 and 2023, the company reported that it released 1,244 pounds and 1,263 pounds of O-T, respectively.
In September, the DEC released a plume map showing a roughly half-mile area around the plant where the chemical is being released into the air.
Critics argue that the data used by the agency to generate the map is flawed as it is based on results from just two of 13 stacks on-site.
They also maintain that the DEC failed to take into account so-called "fugitive" emissions, which include leaks from pipes and other equipment and ventilation systems.
Kelly Cloyd, a retired DEC geologist who attended Thursday's meeting, said the most recent tests done by Goodyear in 2022 were rejected by the DEC because they were not performed in keeping with guidelines set by the U.S. Environmental Protection Agency.
As a result, he said, the DEC is working with inaccurate information and that the true impact on the community may prove to be much higher following updated testing and a more accurate accounting of "fugitive" emissions.
"One of the big problems with where we are is we really don't know what the community's been exposed to," Cloyd said.
Earlier this month, the DEC entered into a consent order with Goodyear that will require the company to install temporary pollution control devices next month and permanent control measures by October 2026.
The agreement allows Goodyear to perform additional stack testing only after the controls have been implemented.
"One of the things we've asked for that DEC has not demanded from Goodyear is stack testing prior to the installation of the equipment so we have some idea of what people have been exposed to," Cloyd said. "That seems kind of critical to me."
Organizers of Thursday's meeting urged residents in attendance to follow their lead and contact Gov. Kathy Hochul's office to encourage her to direct the DEC to amend the consent order. They want the DEC to require Goodyear to immediately install temporary pollution controls and to commit to the installation of permanent equipment to reduce O-T emissions by 90% as soon as possible. They also want state regulators to mandate new stack testing in keeping with EPA guidelines before any new pollution control measures come online.
"We're asking that the equipment be installed in two months, not in the two years that the DEC has recently given Goodyear," said Matteo Anello, who has lived in his family home on 56th Street just east of the plant for decades.
A trio of local elected officials attended Thursday's meeting, including Falls lawmakers Donta Myles and Brian Archie and Niagara County Legislator Jeffrey Elder. All three expressed willingness to join residents in pushing state officials to address local concerns about the plant's operation.
"It's going to take a collective effort from all of our local governing bodies," Myles said.
Elder said he intends to bring the issue up for consideration at a future county legislature meeting.
"When we are collectively together, we can make things happen," Elder said.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
The most depressing jobs in the country revealed in new study
Job seekers may want to consider the toll that specific careers can have on their mental health. A huge new study published on Friday examined the relationship between careers and depression rates. The study analyzed survey data from 536,279 workers across 37 states from 2015 to 2019. Out of half a million U.S. workers, 80,319 of them admitted to being diagnosed with depression at some point during their lives, with women being diagnosed twice as often as men. Separating the results by industry, the study saw that people who worked in community and social services had the highest rate of lifelong diagnosed depression at 20.5 percent. The second highest on the list was food prep and serving jobs at 20.1 percent. Other industries with high lifetime diagnosed depression rates are: arts, entertainment, sports, and media at 18.6 percent; accommodation and food services at 18.4 percent; health and social assistance at 18.2 percent; retail trade at 17.7 percent; and legal, education, and library jobs tied at 16.1 percent. Industries with lower lifetime diagnosed depression rates included mining jobs at 6.7 percent, construction at 8.9 percent, and agriculture and engineering jobs at nine percent. Although mining and construction may have lower depression rates, those industries also have the highest suicide rates among U.S. workers. The researchers suggest that the gap may be explained because blue-collar men are less likely to seek mental services due to a preexisting stigma or limited access in rural areas. Despite the results of the study, there are some jobs out there that are almost stress-free and also come with a large paycheck. Back in December 2024, Resume Genius released its list of the highest-paying jobs that also reported low levels of stress. Their study described 'low-stress jobs' as ones that typically require fewer demands, more predictable work hours, supportive environments, and manageable workloads. All of the jobs on the list required the person to have at least a Bachelor's degree. The list was compiled using data from the U.S. Bureau of Labor Statistics (BLS) and the career site O*NET Online. The high-stress jobs were filtered out using O*NET and then cross-referenced against the BLS's Occupational Outlook Handbook, with the national median salary set at $48,060 and viewing jobs that showed 'faster-than-average growth.' The best jobs included: water source specialist, astronomer, actuary, environmental economist, mathematician, and geographer.
Yahoo
a day ago
- Yahoo
KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("α-KLOTHO")
Recent clinical and pre-clinical studies and analysis indicates the potential to increase lifespan and reduce age-associated degeneration in multiple organ systems has be realized with a focus on the human gene called Klotho. NEW YORK, June 9, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biogenetics company announced the findings of pre-clinical studies indicating the potential of elevating Klotho gene expression to simultaneously reduce the age-associated degeneration in multiple organs, increasing both life and health span. Pioneering discoveries by Professor Makoto Kuro-O in 1997 showed that Klotho concentrations in the blood were directly associated with lifespan of mammals – the lower the Klotho blood levels the shorter the lifespan. Kuro-O's laboratory then published the first evidence that genetic over expression of the full-length form of Klotho in mice, increased in lifespan of mice of up to 30%-40% longer compared to the normal mouse lifespan. Since then, the Klotho protein has gained much attention because of its ability to influence key biological pathways involved in metabolism, inflammation and tissue repair, which are closely linked to the aging process. A series of experiments led by Joan Roig-Soriano and colleagues, published in the February 2025 edition of Molecular Therapy, highlights the promising role of the naturally occurring secreted form of the Klotho protein ("s-KL") and its effects on healthy aging mice and mice with a rapidly aging phenotype. Key observations were that, while aging is a major risk factor for many pathologies, including cognitive decline, neuroinflammation, sarcopenia, and osteoporosis, the secreted protein s-KL has emerged as a potentially promising therapeutic anti-aging molecule due to its many biological effects involving multiple pathways related to cell injury, stress, and inflammation. The s-KL was administered using an adeno-associated virus serotype 9 delivery vector (AAV9) that expressed the secreted KL protein isoform and efficiently increased the concentration of s-KL in serum, resulting in a 20% increase in lifespan. Dr. Joseph Sinkule, the CEO of Klotho Neurosciences (KLTO) commented that "KLTO has secured an exclusive worldwide license for s-Kl from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA) in Spain. As a result, we have the exclusive use of patents issued in the USA, Europe, and China covering a secreted splice variant of mammalian Klotho referred to as s-KL, as a treatment for neurodegenerative and age -related disorders. Professor Makoto Kuro-O is also a scientific advisor to KLTO. This recently published paper provides further credence to our development of s-KL as a treatment to reduce age-associated degeneration where, as a company, KLTO has a particular focus on neurodegenerative diseases such as ALS, Alzheimer's and Parkinson's disease. The results disclosed in the paper show the potential of elevating s-KL protein expression, resulting in the reduction of age-associated degeneration in multiple organs, increasing both life and health span". About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and it's novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization. For more information, contact:Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFOjeff@ Website: Forward-Looking Statements: This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC's website, All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. View original content to download multimedia: SOURCE Klotho Neurosciences, Inc.
Yahoo
2 days ago
- Yahoo
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025
SAN JOSE, Calif., June 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, and the principal investigator of the Phase 1 clinical trial of Anixa's ovarian cancer CAR-T immunotherapy, will present an e-poster at the European Society for Medical Oncology ("ESMO") Gynaecological Cancers Congress 2025, to be held on June 19-21, 2025 in Vienna, Austria. Presentation Details: Title: Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA) Session Type: E-Poster Poster No.: 145eTiP About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit or follow Anixa on Twitter, LinkedIn, Facebook and YouTube. Forward-Looking StatementsStatements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact:Mike CatelaniPresident, COO & CFOmcatelani@ View original content to download multimedia: SOURCE Anixa Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data